Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib in
treating patients with advanced or metastatic breast cancer that overexpresses HER2.